U.S. License Holder:
Sandoz Inc.
Date of License:
August-30-2016
Last Update:
Nov-15-2024
FDA-Approved Indications
ERELZI (etanercept-szzs) is a tumor necrosis factor (TNF) blocker indicated for the treatment of:
Rheumatoid Arthritis (RA);
Polyarticular Juvenile Idiopathic Arthritis (JIA) in patients aged 2 years or older;
Psoriatic Arthritis (PsA);
Ankylosing Spondylitis (AS);
Plaque Psoriasis (PsO) in patients 4 years or older.
Approved Foreign Follow-On Biologics / Biosimilars
Biosimilars Approved In Canada
Erelzi (Sandoz) (April-2017)
Biosimilars Approved In The E.U.
Erelzi (Sandoz) (June-2017)
U.S. Patent Litigations
